Social Links

Follow on Facebook Follow on TwitterFollow EiR on PinterestFollow EiR on Instagram

Xpert Access


Login To Get Involved!

Forgot your username?

Forgot your password?


Join Us At EiR Now!

DNRS Roof Banner


Universal AJAX Live Search

Search - Categories
Search - Contacts
Search - Content
Search - Newsfeeds
Search - Weblinks

Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea




Eur J Gastroenterol Hepatol. 2005 Dec;17(12):1357-61.


Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication.


Duman DG, Bor S, Ozutemiz O, Sahin T, Oguz D, Istan F, Vural T, Sandkci M, Isksal F, Simsek I, Soyturk M, Arslan S, Sivri B, Soykan I, Temizkan A, Bessk F, Kaymakoglu S, Kalayc C.


Department of Gastroenterology, Marmara University, School of Medicine, Istanbul, Turkey.


BACKGROUND AND AIM: Antibiotic-associated diarrhoea may develop during or following Helicobacter pylori eradication. We aimed to evaluate the efficacy and safety of Saccharomyces boulardii in preventing antibiotic-associated diarrhoea in patients receiving antibiotics for H. pylori eradication. METHODS: In a multicentre prospective clinical trial, patients with peptic ulcer disease or non-ulcer dyspepsia were enrolled to receive clarithromycin, amoxicillin and omeprazole for H. pylori eradication for 14 days. These patients were then randomized to receive either S. boulardii 500 mg twice daily (treatment group) or no treatment (control group). The primary outcome measure was the development of diarrhoea during (treatment period) or within 4 weeks after treatment (follow-up period). RESULTS: Of the 389 patients that were enrolled, 376 completed the study. Within the treatment period, diarrhoea developed in 5.9% of patients in the treatment group and in 11.5% of patients in the control group (P = 0.049); and in the follow-up period, diarrhoea developed in 1.0% of patients in the treatment group and in 3.8% of patients in the control group (P = 0.09). Overall diarrhoea rates throughout the whole study period were 6.9% in the treatment group and 15.6% in the control group (P = 0.007). No significant difference was observed between the treatment and control groups in terms of adverse events. CONCLUSION: S. boulardii is an effective and safe treatment for prevention of antibiotic-associated diarrhoea when given concomitantly to patients receiving H. pylori eradication.


Publication Types:
Multicenter Study
Randomized Controlled Trial


PMID: 16292090 [PubMed - indexed for MEDLINE]

Full Article Available Online



Please Help Support EiR with a Positive Google Review!

Review on Google


If you like EiR and / or enoyed this content; please help us keep going by leaving a Positive Google Review: 

P.S. This is entirely secure, we collect no data other than what is freely available from Google and you can remain anonymous!


Related Articles:


Mold Testing & Sanitizer:







  • No comments found

Leave your comments

Post comment as a guest

0 Character restriction
Your text should be more than 25 characters
Your comments are subjected to administrator's moderation.
terms and condition.

Adsense Responsive BottomBanner